PRESS RELEASE published on 04/04/2023 at 14:45, 2 years 8 months ago The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate
PRESS RELEASE published on 03/23/2023 at 21:30, 2 years 8 months ago Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference
PRESS RELEASE published on 03/16/2023 at 21:10, 2 years 8 months ago Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting
PRESS RELEASE published on 03/15/2023 at 13:10, 2 years 8 months ago Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
PRESS RELEASE published on 02/10/2023 at 15:00, 2 years 9 months ago Edesa Biotech Reports Fiscal 1st Quarter 2023 Results
PRESS RELEASE published on 02/01/2023 at 14:15, 2 years 10 months ago Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
PRESS RELEASE published on 01/17/2023 at 14:30, 2 years 10 months ago Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug
Published on 12/05/2025 at 02:35, 3 hours 28 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 3 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 58 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 3 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 32 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 12 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 37 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 48 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 52 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 3 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 18 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 19 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 2 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
